Genfit Full Year 2024 Earnings: EPS: €0.03 (vs €0.58 loss in FY 2023)

Genfit (EPA:GNFT) Full Year 2024 Results

Key Financial Results

• Revenue: €70.9m (up 106% from FY 2023).
• Net income: €1.51m (up from €28.9m loss in FY 2023).
• Profit margin: 2.1% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
• EPS: €0.03 (up from €0.58 loss in FY 2023).

We've discovered 1 warning sign about Genfit. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genfit Earnings Insights

In the last 12 months, the only revenue segment was Research and Development of Innovative Medicines and Diagnostic Solutions contributing €70.9m. The largest operating expense was Research & Development (R&D) costs, amounting to €47.2m (68% of total expenses). Explore how GNFT's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 25% growth forecast for the Biotechs industry in France.

Performance of the French Biotechs industry.

The company's shares are up 16% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Genfit you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.